Azacitidine and DNMT3A emerge as candidate targets in osteoarthritis synovium

Osteoarthritis remains a whole-joint disorder without approved disease-modifying drugs, and the synovium — particularly fibroblast-like synoviocytes (FLS) — is increasingly recognized as a key player in disease progression. A new bioinformatic drug-repurposing study, published in Clinical Epigenetics, set out to identify novel synovial therapeutic targets by mining transcriptomic data and querying drug-response databases, rather than by screening compounds one by one in the laboratory.

The researchers analyzed transcriptomic datasets of human osteoarthritis (OA) and non-OA knee synovium to find differentially expressed genes (DEGs) common across datasets. Sixty-one DEGs overlapped across three synovial datasets, and 60 genes with concordant direction of change were used to query the Connectivity Map (CMap), a computational resource that matches disease gene-expression signatures against drug-induced signatures. The goal was to predict compounds capable of reversing the OA-associated expression pattern in synovial tissue.

Azacitidine stood out among the compounds showing strong negative connectivity — meaning its expression footprint opposed the OA signature. Azacitidine is a known inhibitor of DNA methyltransferases, and its annotated target DNMT3A was found to be increased in human OA synovium and in OA-FLS. This convergence between the computational prediction and the observed expression change in patient tissue made the DNMT3A pathway the leading candidate for experimental follow-up.

To test the prediction, the team worked with primary human OA fibroblast-like synoviocytes. Both azacitidine treatment and direct DNMT3A knockdown reduced global DNA methylation and lowered the expression of inflammatory and catabolic genes in these cells. Because synovial inflammation can influence neighboring cartilage, the researchers also ran conditioned-medium experiments, which supported an indirect contribution of OA-FLS to the inflammatory activation of chondrocytes — the cells that maintain cartilage.

The findings were then extended into an animal setting. In a surgically induced rat knee OA model, intra-articular delivery of azacitidine or of shRNA targeting DNMT3A attenuated both synovitis and cartilage damage. The study's authors frame their findings as supporting further evaluation of selective, locally delivered DNMT3A inhibition, and the rat experiments used intra-articular delivery.

It is important to be precise about what the study does and does not show. The rat experiments used a surgically induced model, which does not capture the full complexity of human OA, and the human work was conducted in cells from patients with OA rather than in clinical trials. The authors explicitly state that locus-specific methylation studies, safety testing, and validation in additional OA models are required before any disease-modifying or clinical efficacy can be inferred.

Methodologically, the study used a 60-gene directional signature from patient synovium to query the Connectivity Map and rank candidate compounds capable of reversing the OA-associated expression pattern, then evaluated the leading candidate pathway in primary human OA-FLS and a rat OA model. The study combines computational prediction, patient-tissue expression data, cell-based perturbation, and an in vivo intervention in support of the DNMT3A hypothesis, though the authors note that further validation is required.

Whether selectively inhibiting DNMT3A in the synovium can slow or halt cartilage degradation in patients remains an open question, and the authors’ own caveats about safety, methylation specificity, and model validation mark the necessary next steps. For now, the study offers a concrete, testable target for locally delivered epigenetic therapy in osteoarthritis, a condition for which new disease-modifying options are urgently sought.

Subject of Research: Epigenetic drug repurposing for osteoarthritis targeting DNMT3A in synovial fibroblasts

Article Title: Screening of potential therapeutic drugs for osteoarthritis based on CMap analysis and investigation of their mechanisms of action

Article References: Ding, Z., Chen, Y., Wu, S., Malik, M. A., Zhang, W., Huang, J., & Cao, X. (2026). Screening of potential therapeutic drugs for osteoarthritis based on CMap analysis and investigation of their mechanisms of action. Clinical Epigenetics. https://doi.org/10.1186/s13148-026-02250-6

Image Credits: AI Generated

DOI: 10.1186/s13148-026-02250-6

Keywords: osteoarthritis, DNMT3A, azacitidine, drug repurposing, Connectivity Map, fibroblast-like synoviocytes, epigenetics, DNA methylation, synovitis, rat model, Screening, potential